Text
Amlodipine in Hypertension : 24 - Hour Blood Pressure Control, Hormonal and Renal Effects
The purpose of the present study is to evaluate the effects of amlodipine once daily on 24-hours BP control, hormonal and renal hemodynamic parameters, in patients, in patients with essential hypertension. This study was was an open non-comparative study of amlodipine 5-10 mg once daily, which consisted of two phases : a 2-weeks placebo run-in period and an 8-week active treatment with amloidipine. At the and of placebo phase and at the end of treatment phase, we measured ambulatory BP for 24-hours period, PRA, plasma insulin and ANP, 24-hours urinary output of catecholamines, GFR and ERPF. Thirty patients (19 men and 11 women) with a mean age of 47.8 years (range of 24-65 years) were recruited into this study. After 8 weeks of amlodipine therapy, mean 24 - hour BP percent SD was reduced from 160.6 percent 15.9/103.6 percent 5.5 to 134.3 percent 12.7/81.7 percent 4.0 mmHg (p less than 0.001) without altering the circadian pattern. No significant changes in HR was observed. After treatment, mean PRA percent SD increased from 1.74 percent 0.56 to 1.89 percent 0.54 ng/mlh, plasma ANP from 52.1 percent 12.6 to 54.7 percent 11.0 pg/ml, plasma insulin from 19.9 percent 4.2 to 21.0 percent 4.3 micron U/ml, GFR from 112.1 percent 11.5 to 115.8 percent 11.6 ml/min and ERPF from 552.0 percent 55.8 to 595.2 percent 52.9 ml/min (p less 0.05 to less than 0.001). Urinary catecholamines did not differ significantly between the placebo and amlodipine phases. In conclusion, amlodipine once daily is an effective antihypertensive throughout 24 hours without altering the circulation variation, and has no clinically significant effect on pressor hormones nor renal function.
No other version available